{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:37:35Z","timestamp":1776857855551,"version":"3.51.2"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sorafenib is a multi-kinase inhibitor increasingly used in veterinary oncology, but information regarding its potential adverse hematologic effects in dogs remains limited. A 50\u00a0kg neutered male Labrador Retriever with previously treated intranasal sarcoma was treated with sorafenib (5\u00a0mg\/kg PO q24h) based on tyrosine kinase receptor profiling that identified 60% overexpression of platelet-derived growth factor receptor. The dog remained clinically stable for 132\u00a0days before developing worsening nasal discharge, increased epistaxis, and respiratory effort. Hematologic testing identified a platelet count of 130\u00a0\u00d7\u00a0103\/\u03bcL with clumping, normal prothrombin time, activated partial thromboplastin time, and normal D-dimer concentration. Computed tomography did not indicate appreciable tumor progression. Viscoelastic assessment demonstrated delayed clot initiation and markedly decreased clot development and firmness, consistent with a hypocoagulable profile. Sorafenib was discontinued, and serial viscoelastic testing on days 149, 170, and 191 showed progressive improvement with normalization of clot parameters, paralleling the resolution of clinical signs. This case documents reversible, sorafenib-associated coagulopathy in a dog and illustrates the diagnostic utility of viscoelastic testing when evaluating worsening epistaxis in dogs receiving tyrosine kinase inhibitors.<\/jats:p>","DOI":"10.1093\/jvimsj\/aalag075","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:40:48Z","timestamp":1776854448000},"source":"Crossref","is-referenced-by-count":0,"title":["Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5626-0755","authenticated-orcid":false,"given":"Doyun","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Oncology, BON Animal Medical Center , Suwon 16305 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5590-4224","authenticated-orcid":false,"given":"Yunsung","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Oncology, BON Animal Medical Center , Suwon 16305 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6067-6964","authenticated-orcid":false,"given":"Seonghoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Oncology, BON Animal Medical Center , Suwon 16305 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-2574","authenticated-orcid":false,"given":"Mihyun","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Oncology, BON Animal Medical Center , Suwon 16305 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3675-6091","authenticated-orcid":false,"given":"Yongsun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Oncology, BON Animal Medical Center , Suwon 16305 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026042206404119500_ref1","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"2026042206404119500_ref2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2026042206404119500_ref3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"2026042206404119500_ref4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2026042206404119500_ref5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/VMRR.S149678","article-title":"Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer","volume":"8","author":"Foskett","year":"2017","journal-title":"Vet Med (Auckl)"},{"key":"2026042206404119500_ref6","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/cancers12051272","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma in dogs: a prospective pilot study","volume":"12","author":"Marconato","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026042206404119500_ref7","doi-asserted-by":"publisher","first-page":"8438","DOI":"10.3390\/ijms25158438","article-title":"Immunohistochemistry screening of different tyrosine kinase receptors in canine solid tumors: part I\u2014proposal of a receptor panel to predict therapies","volume":"25","author":"Dos Anjos","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026042206404119500_ref8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1292\/jvms.22-0542","article-title":"Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma","volume":"85","author":"Osada","year":"2023","journal-title":"J Vet Med Sci"},{"key":"2026042206404119500_ref9","doi-asserted-by":"publisher","first-page":"S948","DOI":"10.4103\/0973-1482.188430","article-title":"Bleeding risk in cancer patients treated with sorafenib: a meta-analysis of randomized controlled trials","volume":"14","author":"Dai","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"2026042206404119500_ref10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/vcp.12926","article-title":"Establishment of normal reference intervals in dogs using a viscoelastic point-of-care coagulation monitor and its comparison with thromboelastography","volume":"49","author":"Buriko","year":"2020","journal-title":"Vet Clin Pathol"},{"key":"2026042206404119500_ref11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/vcp.13198","article-title":"Comparison of a viscoelastic point-of-care coagulation monitor with thromboelastography in sick dogs with hemostatic abnormalities","volume":"52","author":"Buriko","year":"2023","journal-title":"Vet Clin Pathol"},{"key":"2026042206404119500_ref12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2460\/ajvr.24.07.0196","article-title":"Point-of-care viscoelastic coagulation monitoring device shows promise for informing resuscitation strategies in a canine hemorrhagic shock model","volume":"86","author":"Baird","year":"2025","journal-title":"Am J Vet Res"},{"key":"2026042206404119500_ref13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"2026042206404119500_ref14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"2026042206404119500_ref15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10456-018-9598-5","article-title":"Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab","volume":"21","author":"Walraven","year":"2018","journal-title":"Angiogenesis"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/2\/aalag075\/68134637\/aalag075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/2\/aalag075\/68134637\/aalag075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:40:48Z","timestamp":1776854448000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag075\/8660767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag075","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"aalag075"}}